The appallingly low rates of patient participation in cancer clinical trials, especially in the community setting, is no secret. The fact is that 98 percent% of our patient population isn’t aware of available trials, doesn’t know how to apply, or is under too much financial and emotional strain, etc. to even consider joining a trial. The blame for this rightfully falls on the proverbial shoulders of the main stakeholders: the biopharmaceutical industry, healthcare institutions, government, and — yes — patient support groups.
Sadly, the average drop-out rate across clinical trials is 30%. Greenphire has increasingly seen clients focused on increasing completion rates of patient reported outcomes and bolstering compliance using ClinCard. ClinCard has built-in text reminders for upcoming onsite patient visits and the ability to trigger “micropayments” when select tasks are completed.
That’s a wrap on our second DIA global annual meeting workshop, “Setting the Stage for Stakeholder Collaboration.” Everyones engagement turns an idea into real moment of reflection and learning for all. Read more about these collaboration scenerios and what was learned from them.
Part 1 of this two-part article examined the implications the transition to value-based, patient-centric, precision medicine has for drug discovery, development, and deployment, particularly for clinical trials. Part 2 explores precision medicine in more depth regarding the tailored and targeted treatments that aim to match patients to medicines according to particular clinical, demographic, and lifestyle factors.
Many biotechnology/pharmaceutical organizations are in the early stages of developing their risk management process. For the most part, we tend to see this process developing at the clinical trial level. The struggle with implementing these practices solely at the trial level is that it quickly becomes inconsistent and obsolete. Study teams are taking the time to assess risk as it applies to their trial, but the information gained is seldom shared cross-functionally or upward through an organization. It is more of a “going through the motions” type practice — which is then filed away, never to be utilized again.
From banking to e-commerce, cloud computing has transformed the landscape of the world economy. It is also gradually changing the face of the biopharma industry. In the scientific world, effective communication and collaboration are essential to successful outcomes. Although biopharma has been slower than some other industries to adopt cloud-based technologies, the field is increasingly relying on the cloud to advance scientific knowledge.
This is the first part of a two-part article that examines the implications the transition to value-based, patient-centric, precision medicine has for drug discovery, development, and deployment, particularly for clinical trials.
Penn Medicine offers tips for sites considering the use of technology to reduce the administrative burden in clinical research.
To speed trial execution, improve decision making, and streamline clinical operations, many life sciences companies are moving toward modern, cloud-based CTMS applications.
Using disparate systems to manage today’s complex clinical trials can be extremely challenging. This blog provides an in-depth look into how a unified clinical environment drives speed and higher efficiencies.
|
|
|
|
|
|
|
|
|